Likewise, localised CYP activity in tumour cells can have a deleterious pharmacologic effect when active drugs are inactivated by these enzymes, leading to drug resistance; this, in turn, contributes to reduced drug doses in the tumour tissue and longer-term cancer recurrence. The gene discussed is PPIG; the disease is neoplasm.